Literature DB >> 28318386

Towards precision oncology in RET-aberrant cancers.

Vivek Subbiah1, Jason Roszik1.   

Abstract

Entities:  

Keywords:  NGS; RET; TCGA; next generation sequencing; precision oncology

Mesh：

Substances：

Year:  2017        PMID： 28318386      PMCID： PMC5444346          DOI： 10.1080/15384101.2017.1302235

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 3.  RET tyrosine kinase signaling in development and cancer.

Authors:  Elena Arighi; Maria Grazia Borrello; Hannu Sariola
Journal:  Cytokine Growth Factor Rev       Date:  2005 Aug-Oct       Impact factor: 7.638

4.  RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.

Authors:  Shumei Kato; Vivek Subbiah; Erica Marchlik; Sheryl K Elkin; Jennifer L Carter; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

5.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

6.  Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.

Authors:  Vivek Subbiah; Jenny Berry; Michael Roxas; Nandita Guha-Thakurta; Ishwaria Mohan Subbiah; Siraj M Ali; Caitlin McMahon; Vincent Miller; Tina Cascone; Shobha Pai; Zhenya Tang; John V Heymach
Journal:  Lung Cancer       Date:  2015-04-22       Impact factor: 5.705

7.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.

Authors:  A Hunter Shain; Maria Garrido; Thomas Botton; Eric Talevich; Iwei Yeh; J Zachary Sanborn; Jongsuk Chung; Nicholas J Wang; Hojabr Kakavand; Graham J Mann; John F Thompson; Thomas Wiesner; Ritu Roy; Adam B Olshen; Alexander Gagnon; Joe W Gray; Nam Huh; Joe S Hur; Klaus J Busam; Richard A Scolyer; Raymond J Cho; Rajmohan Murali; Boris C Bastian
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330
  7 in total
  3 in total

1.  Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Authors:  Roman Groisberg; David S Hong; Jason Roszik; Filip Janku; Apostolia M Tsimberidou; Milind Javle; Funda Meric-Bernstam; Vivek Subbiah
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

Review 2.  Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers.

Authors:  Jacob J Adashek; Aakash P Desai; Alexander Y Andreev-Drakhlin; Jason Roszik; Gilbert J Cote; Vivek Subbiah
Journal:  Mol Cancer Ther       Date:  2021-09-06       Impact factor: 6.261

3.  Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.

Authors:  Jakob M Riedl; Samantha O Hasenleithner; Gudrun Pregartner; Lukas Scheipner; Florian Posch; Karin Groller; Karl Kashofer; Stephan W Jahn; Thomas Bauernhofer; Martin Pichler; Herbert Stöger; Andrea Berghold; Gerald Hoefler; Michael R Speicher; Ellen Heitzer; Armin Gerger
Journal:  Ther Adv Med Oncol       Date:  2021-02-27       Impact factor: 8.168
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.